NXS.AX - Next Science Limited
Next Science Limited
The Zenith Building, Tower A
Suite 1902 Level 19 821 Pacific Highway
Chatswood, NSW 2067
Australia
61 2 8607 5126
https://www.nextscience.com
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees:
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Ms. Judith Mitchell M.B.A. | MD, CEO & Exec. Director | 288.08k | N/A | N/A |
| Dr. Matthew Franco Myntti | Founder & CTO | 366.61k | N/A | N/A |
| Ms. Jacqueline Butler CA (ICAEW) | Chief Financial Officer | 267.91k | N/A | N/A |
| Mr. Jon Swanson | Chief Operating Officer | 265.18k | N/A | N/A |
| Mr. Martyn Jacobs | Head of Investor Relations | N/A | N/A | N/A |
| Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD | Company Sec. | N/A | N/A | N/A |
Description
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the issues in human health caused by biofilms in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for postoperative wound; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Chatswood, Australia.
Corporate governance
Next Science Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
